Ironwood Investment Management LLC Has $530,000 Position in Pfizer, Inc. (PFE)

Ironwood Investment Management LLC maintained its position in Pfizer, Inc. (NYSE:PFE) during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 15,481 shares of the biopharmaceutical company’s stock at the close of the 1st quarter. Ironwood Investment Management LLC’s holdings in Pfizer were worth $530,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors also recently added to or reduced their stakes in PFE. Chevy Chase Trust Holdings Inc. lifted its position in shares of Pfizer by 0.9% during the 1st quarter. Chevy Chase Trust Holdings Inc. now owns 5,428,710 shares of the biopharmaceutical company’s stock valued at $185,715,000 after acquiring an additional 46,366 shares during the period. Peachtree Investment Advisors Inc. lifted its position in shares of Pfizer by 1.3% during the 1st quarter. Peachtree Investment Advisors Inc. now owns 7,516 shares of the biopharmaceutical company’s stock worth $257,000 after buying an additional 100 shares during the last quarter. Atlas Brown Inc. lifted its position in shares of Pfizer by 13.1% during the 1st quarter. Atlas Brown Inc. now owns 35,471 shares of the biopharmaceutical company’s stock worth $1,213,000 after buying an additional 4,096 shares during the last quarter. Pure Financial Advisors Inc. lifted its position in shares of Pfizer by 0.4% during the 1st quarter. Pure Financial Advisors Inc. now owns 22,091 shares of the biopharmaceutical company’s stock worth $756,000 after buying an additional 84 shares during the last quarter. Finally, Manning & Napier Advisors LLC lifted its position in shares of Pfizer by 5.2% during the 1st quarter. Manning & Napier Advisors LLC now owns 719,433 shares of the biopharmaceutical company’s stock worth $24,610,000 after buying an additional 35,433 shares during the last quarter. Hedge funds and other institutional investors own 69.09% of the company’s stock.

In other news, insider Alexander R. Mackenzie sold 7,350 shares of the business’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $34.00, for a total value of $249,900.00. Following the sale, the insider now directly owns 124,774 shares of the company’s stock, valued at approximately $4,242,316. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 7th. The stock was sold at an average price of $33.50, for a total value of $502,500.00. Following the completion of the sale, the insider now directly owns 151,474 shares in the company, valued at $5,074,379. The disclosure for this sale can be found here. Over the last three months, insiders sold 426,291 shares of company stock worth $14,475,911. Insiders own 0.06% of the company’s stock.

Pfizer, Inc. (PFE) traded up 3.307% on Tuesday, hitting $35.455. The stock had a trading volume of 21,541,555 shares. The company has a market cap of $210.86 billion, a P/E ratio of 25.936 and a beta of 1.00. The stock has a 50 day moving average price of $33.35 and a 200 day moving average price of $33.48. Pfizer, Inc. has a 1-year low of $29.83 and a 1-year high of $35.75.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 EPS for the quarter, topping analysts’ consensus estimates of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The firm had revenue of $12.90 billion for the quarter, compared to analysts’ expectations of $13.08 billion. During the same period in the previous year, the firm posted $0.64 EPS. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. On average, equities research analysts expect that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.

The business also recently declared a quarterly dividend, which was paid on Friday, September 1st. Stockholders of record on Friday, August 4th were given a $0.32 dividend. The ex-dividend date of this dividend was Wednesday, August 2nd. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.73%. Pfizer’s dividend payout ratio is currently 94.12%.

Several brokerages recently weighed in on PFE. Jefferies Group LLC set a $35.00 price objective on Pfizer and gave the stock a “neutral” rating in a research report on Wednesday, August 2nd. Berenberg Bank set a $39.00 price objective on Pfizer and gave the stock a “neutral” rating in a research report on Tuesday, August 1st. Morgan Stanley restated a “neutral” rating and set a $35.00 price objective (down from $38.00) on shares of Pfizer in a research report on Monday, June 12th. Zacks Investment Research upgraded Pfizer from a “sell” rating to a “hold” rating in a research report on Friday, July 14th. Finally, Citigroup Inc. downgraded Pfizer from a “neutral” rating to a “sell” rating and dropped their price objective for the stock from $38.00 to $31.00 in a research report on Tuesday, May 16th. Two investment analysts have rated the stock with a sell rating, eleven have assigned a hold rating and ten have issued a buy rating to the stock. Pfizer has an average rating of “Hold” and a consensus target price of $37.61.

WARNING: This piece of content was originally published by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2017/09/12/ironwood-investment-management-llc-has-530000-position-in-pfizer-inc-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply